Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.
Skip to main content


Germany's Merck sees boost from labs supplies earnings

1 minute read

A logo of drugs and chemicals group Merck KGaA is pictured in Darmstadt, Germany January 28, 2016. REUTERS/Ralph Orlowski/File Photo

Germany's Merck (MRCG.DE) on Wednesday said its Life Science business, a leading maker of biotech lab supplies and gear, saw core earnings jump more than 43% in the first quarter, driven by the pharma industry's efforts to fight the coronavirus pandemic.

Adjusted earnings before interest, tax, depreciation and amortization at the division rose to 793 million euros ($961 million).

The company, which also makes pharmaceuticals and specialty chemicals, on May 4 reported better-than-expected quarterly earnings for the group ahead of schedule.

At the time it said it expected 2021 adjusted earnings before interest, tax, depreciation and amortization (EBITDA) of 5.4-5.8 billion euros, up from 5.2 billion last year. It reaffirmed that guidance on Wednesday.

($1 = 0.8249 euros)

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters